Treatment options
| TREATMENT APPROACH | PATIENT COHORT | LDL-C TARGETS | hsCRP TESTING | BENEFITS | RISKS |
|---|---|---|---|---|---|
| Guideline-based (treat to target) | High FRS or High LDL-C level | Yes | Selected groups | Peer support Consistency Optimization of benefits | Suboptimal physician uptake Suboptimal patient compliance Reliance on surrogate markers and targets |
| Expedient | High FRS | No | No | Simplicity Lower cost Two-thirds of benefit realized | Maximal benefit not realized No prospective validation studies exist |
FRS—Framingham risk score, hsCRP—high-sensitivity C-reactive protein, LDL-C—Low density lipoprotein cholesterol.